Your session is about to expire
← Back to Search
Virus Vaccine
mRNA-1653 for Human Metapneumovirus and Human Parainfluenza Infection
Phase 1
Waitlist Available
Research Sponsored by ModernaTX, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Summary
This trial is testing a new vaccine that helps the body fight off two types of respiratory viruses. It will be tested on healthy adults and young children who have been exposed to these viruses before. The vaccine works by teaching the body to recognize and combat these viruses.
Eligible Conditions
- Human Metapneumovirus and Human Parainfluenza Infection
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Trial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: mRNA-1653, Adult participantsExperimental Treatment1 Intervention
Participants will receive 1 of 2 doses of mRNA-1653, administered via intramuscular injection, on Day 1 and Day 57.
Group II: mRNA-1653 Pediatric participantsExperimental Treatment1 Intervention
Participants will receive 1 of 2 possible doses of mRNA-1653, administered via intramuscular injection, on Day 1 and Day 57.
Group III: Placebo, Adult participantsPlacebo Group1 Intervention
Participants will receive mRNA-1653-matching placebo, administered via intramuscular injection, on Day 1 and Day 57.
Group IV: Placebo, Pediatric participantsPlacebo Group1 Intervention
Participants will receive mRNA-1653-matching placebo, administered via intramuscular injection, on Day 1 and Day 57.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
mRNA-1653
2017
Completed Phase 1
~180
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
ModernaTX, Inc.Lead Sponsor
120 Previous Clinical Trials
61,587,961 Total Patients Enrolled
1 Trials studying Human Metapneumovirus and Human Parainfluenza Infection
124 Patients Enrolled for Human Metapneumovirus and Human Parainfluenza Infection
Share this study with friends
Copy Link
Messenger